Global Biotech goes China – Institut Pasteur Shanghai launches a unique platform for global biotech companies in China

peutic areas, with 2.2 million cancer deaths, 170,000 deaths from cardiovascular disease, 90 million diabetics and 140 million chronic carriers of Hepatitis B and C reported in 2009 [3, 4]. Over the counter medicines (OTC) and traditional Chinese medicine still account for a large percentage of sales in the China pharmaceutical market but the market share taken by patented products is increasing rapidly [5]. These products enter a market that is also transformed by the massive healthcare reforms led by the Chinese Ministry of Health, which injected US$ 123bn to create a healthcare system aiming at universal coverage and intellectual property law reforms [6].